Oyagüez Itziar, Gómez-Peralta Fernando, Artola Sara, Carrasco Francisco J, Carretero-Gómez Juana, García-Soidan Javier, Gómez-Huelgas Ricardo, Merino-Torres Juan F, Pérez Antonio
Pharmacoeconomics and Outcomes Research Iberia (PORIB), Paseo Joaquín Rodrigo 4 - letra I, Pozuelo de Alarcón, 28224, Madrid, Spain.
Unidad de Endocrinología y Nutrición, Hospital General de Segovia, Segovia, Spain.
Diabetes Ther. 2021 Sep;12(9):2329-2342. doi: 10.1007/s13300-021-01064-4. Epub 2021 May 4.
FreeStyle Libre 2 system is a sensor-based flash-monitoring system that measures interstitial fluid glucose. The study aimed to compare cost of FreeStyle Libre 2 system and self-monitoring of blood glucose (SMBG) in the type 2 diabetes mellitus (T2DM) population from the Spanish Health System perspective.
On the basis of data collected from a literature review, the cost of glucose monitoring was modelled for patients with T2DM on a basal-bolus insulin regimen. The cost estimate included annual consumption for glucose monitoring (strips, lancets and sensors) and severe hypoglycaemic events (SHE) management. A published rate of SHE (2.5 episodes/patient-year) was considered. A reduction of SHE (- 48.8%) associated with FreeStyle Libre 2 system, derived from the REPLACE trial, was applied. Hospital attendance for 20.5% of SHEs (with subsequent hospitalization in 16.0%) was applied. Consumption of strips and lancets was set at 6/day for SMBG (derived from national monitoring recommendations), and 0.2/day for FreeStyle Libre 2 system users, with 26 FreeStyle Libre 2 sensors/year. Unitary costs (€, year 2020 excluding VAT) were derived from literature (€0.28/strip; €0.09/lancet; €3.09/daily FM sensor; €3804/hospitalized SHE; €1794/hospital-attended non-admitted SHE; €389/community-attended SHE).
Costs were €2700 and €2120/year/patient using SMBG or FreeStyle Libre 2 system, respectively. For 1000 patients with T2DM using basal-bolus insulin, 1220 SHEs/year (with 48 hospitalizations) could be prevented and FreeSytle Libre 2 system could generate cost savings of up to €580,953/year versus SMBG (- 21.5%).
FreeStyle Libre 2 system is a potential cost-saving strategy in patients with T2DM in Spain on a basal-bolus insulin regimen.
FreeStyle Libre 2系统是一种基于传感器的闪光监测系统,用于测量组织间液葡萄糖。本研究旨在从西班牙卫生系统的角度比较FreeStyle Libre 2系统与2型糖尿病(T2DM)人群自我血糖监测(SMBG)的成本。
基于文献综述收集的数据,对接受基础-餐时胰岛素治疗方案的T2DM患者的血糖监测成本进行建模。成本估算包括血糖监测的年度消耗量(试纸、采血针和传感器)以及严重低血糖事件(SHE)的管理成本。采用已发表的SHE发生率(2.5次/患者-年)。应用了来自REPLACE试验的与FreeStyle Libre 2系统相关的SHE减少率(-48.8%)。设定20.5%的SHE需要就医(其中16.0%随后住院)。SMBG的试纸和采血针消耗量设定为每天6次(源自国家监测建议),FreeStyle Libre 2系统使用者为每天0.2次,每年使用26个FreeStyle Libre 2传感器。单位成本(2020年欧元,不含增值税)来自文献(0.28欧元/试纸;0.09欧元/采血针;3.09欧元/每日闪光监测传感器;3804欧元/住院SHE;1794欧元/就医但未住院的SHE;389欧元/社区处理的SHE)。
使用SMBG或FreeStyle Libre 2系统时,每位患者每年的成本分别为2700欧元和2120欧元。对于1000名接受基础-餐时胰岛素治疗的T2DM患者,每年可预防1220次SHE(其中48次住院),与SMBG相比,FreeStyle Libre 2系统每年可节省成本高达580,953欧元(-21.5%)。
对于西班牙接受基础-餐时胰岛素治疗方案的T2DM患者,FreeStyle Libre 2系统是一种潜在的节省成本策略。